KR20040029375A - 개, 고양이 및 말에서 결함있는 행태를 변화시키기 위한ｎｋ-1 수용체 길항제의 용도 - Google Patents
개, 고양이 및 말에서 결함있는 행태를 변화시키기 위한ｎｋ-1 수용체 길항제의 용도 Download PDFInfo
- Publication number
- KR20040029375A KR20040029375A KR10-2004-7000901A KR20047000901A KR20040029375A KR 20040029375 A KR20040029375 A KR 20040029375A KR 20047000901 A KR20047000901 A KR 20047000901A KR 20040029375 A KR20040029375 A KR 20040029375A
- Authority
- KR
- South Korea
- Prior art keywords
- methoxybenzylamino
- azabicyclo
- diphenylmethyl
- amino
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title claims abstract description 48
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title claims abstract description 48
- 229940044551 receptor antagonist Drugs 0.000 title claims abstract description 40
- 239000002464 receptor antagonist Substances 0.000 title claims abstract description 40
- 241000283086 Equidae Species 0.000 title claims description 4
- 241000282326 Felis catus Species 0.000 title claims description 4
- 230000002159 abnormal effect Effects 0.000 claims abstract description 60
- 238000000034 method Methods 0.000 claims abstract description 39
- 230000006400 anxiety behaviour Effects 0.000 claims abstract description 38
- 241000282472 Canis lupus familiaris Species 0.000 claims description 65
- 230000006399 behavior Effects 0.000 claims description 44
- 238000011282 treatment Methods 0.000 claims description 41
- 150000001875 compounds Chemical class 0.000 claims description 40
- 238000012360 testing method Methods 0.000 claims description 28
- -1 2-methoxybenzylamino Chemical group 0.000 claims description 20
- 208000013403 hyperactivity Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 238000000926 separation method Methods 0.000 claims description 9
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- IWNUVCPVRJASIF-CONSDPRKSA-N (2s,3s)-2-benzhydryl-n-(2-methoxy-5-propan-2-ylphenyl)-2-methyl-1-azabicyclo[2.2.2]octan-3-amine Chemical compound COC1=CC=C(C(C)C)C=C1N[C@@H]1[C@@](C(C=2C=CC=CC=2)C=2C=CC=CC=2)(C)N2CCC1CC2 IWNUVCPVRJASIF-CONSDPRKSA-N 0.000 claims description 6
- CAWVBTFOZJKLOD-LAUBAEHRSA-N (2s,3s)-2-phenyl-3-[[2-propan-2-yloxy-5-(trifluoromethoxy)phenyl]methyl]piperidin-1-amine Chemical compound CC(C)OC1=CC=C(OC(F)(F)F)C=C1C[C@H]1[C@@H](C=2C=CC=CC=2)N(N)CCC1 CAWVBTFOZJKLOD-LAUBAEHRSA-N 0.000 claims description 6
- HDGOKGLEAJIUED-LAUBAEHRSA-N (2s,3s)-3-[[5-tert-butyl-2-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-1-amine Chemical compound CC(C)(C)C1=CC=C(OC(F)(F)F)C(C[C@H]2[C@H](N(N)CCC2)C=2C=CC=CC=2)=C1 HDGOKGLEAJIUED-LAUBAEHRSA-N 0.000 claims description 6
- DTQNEFOKTXXQKV-HKUYNNGSSA-N (2s,3s)-n-[(2-methoxyphenyl)methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)NCCC1 DTQNEFOKTXXQKV-HKUYNNGSSA-N 0.000 claims description 6
- 230000029142 excretion Effects 0.000 claims description 6
- 230000035622 drinking Effects 0.000 claims description 5
- 230000003370 grooming effect Effects 0.000 claims description 5
- 208000019899 phobic disease Diseases 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 206010034912 Phobia Diseases 0.000 claims description 4
- 230000000949 anxiolytic effect Effects 0.000 claims description 4
- YLTSJRYNMXORGD-WIOPSUGQSA-N (2S,3S)-3-[(2-methoxy-5-phenylphenyl)methyl]-2-phenylpiperidin-1-amine Chemical compound COc1ccc(cc1C[C@@H]1CCCN(N)[C@@H]1c1ccccc1)-c1ccccc1 YLTSJRYNMXORGD-WIOPSUGQSA-N 0.000 claims description 3
- XOKWAQNXHVJYLG-GHTZIAJQSA-N (2S,3S)-3-[(5-ethyl-2-methoxyphenyl)methyl]-2-phenylpiperidin-1-amine Chemical compound CCc1ccc(OC)c(C[C@@H]2CCCN(N)[C@@H]2c2ccccc2)c1 XOKWAQNXHVJYLG-GHTZIAJQSA-N 0.000 claims description 3
- SFTQTBLXIWAZMI-UPVQGACJSA-N (2s,3s)-1-(5-aminopentyl)-n-[(2-methoxyphenyl)methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)N(CCCCCN)CCC1 SFTQTBLXIWAZMI-UPVQGACJSA-N 0.000 claims description 3
- UYMNXIGGKXTLHU-VMPREFPWSA-N (2s,3s)-2-benzhydryl-n-(2-methoxy-5-methylphenyl)-2-methyl-1-azabicyclo[2.2.2]octan-3-amine Chemical compound COC1=CC=C(C)C=C1N[C@@H]1[C@@](C(C=2C=CC=CC=2)C=2C=CC=CC=2)(C)N2CCC1CC2 UYMNXIGGKXTLHU-VMPREFPWSA-N 0.000 claims description 3
- CLEMOHZZIAAIFC-CONSDPRKSA-N (2s,3s)-2-benzhydryl-n-(2-methoxy-5-propylphenyl)-2-methyl-1-azabicyclo[2.2.2]octan-3-amine Chemical compound CCCC1=CC=C(OC)C(N[C@@H]2[C@](N3CCC2CC3)(C)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 CLEMOHZZIAAIFC-CONSDPRKSA-N 0.000 claims description 3
- QFTQKCRAJOXJNK-DKJKITOUSA-N (2s,3s)-2-benzhydryl-n-(5-butan-2-yl-2-methoxyphenyl)-2-methyl-1-azabicyclo[2.2.2]octan-3-amine Chemical compound CCC(C)C1=CC=C(OC)C(N[C@@H]2[C@](N3CCC2CC3)(C)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 QFTQKCRAJOXJNK-DKJKITOUSA-N 0.000 claims description 3
- QSBHMJMADHILTB-KYJUHHDHSA-N (2s,3s)-2-benzhydryl-n-(5-ethyl-2-methoxyphenyl)-2-methyl-1-azabicyclo[2.2.2]octan-3-amine Chemical compound CCC1=CC=C(OC)C(N[C@@H]2[C@](N3CCC2CC3)(C)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 QSBHMJMADHILTB-KYJUHHDHSA-N 0.000 claims description 3
- ZXKQLZMZYWXUJC-CDZUIXILSA-N (2s,3s)-2-benzhydryl-n-(5-tert-butyl-2-methoxyphenyl)-2-methyl-1-azabicyclo[2.2.2]octan-3-amine Chemical compound COC1=CC=C(C(C)(C)C)C=C1N[C@@H]1[C@@](C(C=2C=CC=CC=2)C=2C=CC=CC=2)(C)N2CCC1CC2 ZXKQLZMZYWXUJC-CDZUIXILSA-N 0.000 claims description 3
- WGUXMAYJVLIEJC-SIKLNZKXSA-N (2s,3s)-3-[(2-methoxy-5-propan-2-ylphenyl)methyl]-2-phenylpiperidin-1-amine Chemical compound COC1=CC=C(C(C)C)C=C1C[C@H]1[C@@H](C=2C=CC=CC=2)N(N)CCC1 WGUXMAYJVLIEJC-SIKLNZKXSA-N 0.000 claims description 3
- RMORKLGEDQLZJK-SIKLNZKXSA-N (2s,3s)-3-[(2-methoxy-5-propylphenyl)methyl]-2-phenylpiperidin-1-amine Chemical compound CCCC1=CC=C(OC)C(C[C@H]2[C@H](N(N)CCC2)C=2C=CC=CC=2)=C1 RMORKLGEDQLZJK-SIKLNZKXSA-N 0.000 claims description 3
- BIXFYVZGYCPPHC-NZQKXSOJSA-N (2s,3s)-3-[(5-butyl-2-methoxyphenyl)methyl]-2-phenylpiperidin-1-amine Chemical compound CCCCC1=CC=C(OC)C(C[C@H]2[C@H](N(N)CCC2)C=2C=CC=CC=2)=C1 BIXFYVZGYCPPHC-NZQKXSOJSA-N 0.000 claims description 3
- QVGXCMWXTJZSOB-AOMKIAJQSA-N (2s,3s)-3-[(5-tert-butyl-2-methoxyphenyl)methyl]-2-[3-(trifluoromethoxy)phenyl]piperidin-1-amine Chemical compound COC1=CC=C(C(C)(C)C)C=C1C[C@H]1[C@@H](C=2C=C(OC(F)(F)F)C=CC=2)N(N)CCC1 QVGXCMWXTJZSOB-AOMKIAJQSA-N 0.000 claims description 3
- LXDZLOATCVUXHT-PGRDOPGGSA-N (2s,3s)-3-[(5-tert-butyl-2-methoxyphenyl)methyl]-2-phenylpiperidin-1-amine Chemical compound COC1=CC=C(C(C)(C)C)C=C1C[C@H]1[C@@H](C=2C=CC=CC=2)N(N)CCC1 LXDZLOATCVUXHT-PGRDOPGGSA-N 0.000 claims description 3
- NNNAFENHFFKFSL-KBXCAEBGSA-N (2s,3s)-3-[[2-(difluoromethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-1-amine Chemical compound C([C@@H]1CCCN([C@@H]1C=1C=CC=CC=1)N)C1=CC(OC(F)(F)F)=CC=C1OC(F)F NNNAFENHFFKFSL-KBXCAEBGSA-N 0.000 claims description 3
- RVXVTPXAIUDORO-OXJNMPFZSA-N (2s,3s)-3-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-1-amine Chemical compound CCOC1=CC=C(OC(F)(F)F)C=C1C[C@H]1[C@@H](C=2C=CC=CC=2)N(N)CCC1 RVXVTPXAIUDORO-OXJNMPFZSA-N 0.000 claims description 3
- UGIPKCIBIXXIEF-HNAYVOBHSA-N (2s,3s)-3-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-1-amine Chemical compound COC1=CC=C(OC(F)(F)F)C=C1C[C@H]1[C@@H](C=2C=CC=CC=2)N(N)CCC1 UGIPKCIBIXXIEF-HNAYVOBHSA-N 0.000 claims description 3
- BTXTTXHHCNFOGR-HNAYVOBHSA-N (2s,3s)-3-[[5-chloro-2-(2,2,2-trifluoroethoxy)phenyl]methyl]-2-phenylpiperidin-1-amine Chemical compound C([C@@H]1CCCN([C@@H]1C=1C=CC=CC=1)N)C1=CC(Cl)=CC=C1OCC(F)(F)F BTXTTXHHCNFOGR-HNAYVOBHSA-N 0.000 claims description 3
- JWFRVJYQGQVKBH-ICSRJNTNSA-N (2s,3s)-n-[(2,5-dimethoxyphenyl)methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=C(OC)C(CN[C@@H]2[C@@H](NCCC2)C=2C=CC=CC=2)=C1 JWFRVJYQGQVKBH-ICSRJNTNSA-N 0.000 claims description 3
- HVWRVAHBKREIOR-HKUYNNGSSA-N (2s,3s)-n-[(5-chloro-2-methoxyphenyl)methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=C(Cl)C=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)NCCC1 HVWRVAHBKREIOR-HKUYNNGSSA-N 0.000 claims description 3
- GKJVNRHHOMPGSG-NSIYGSDQSA-N (2s,3s,4s,5r)-2-benzhydryl-3-[(2-methoxy-5-methylphenyl)methylamino]-1-azabicyclo[2.2.2]octane-5-carboxylic acid Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(O)=O)([C@@H]1NCC=1C(=CC=C(C)C=1)OC)[H])C1=CC=CC=C1 GKJVNRHHOMPGSG-NSIYGSDQSA-N 0.000 claims description 3
- ZBFJTKASKIUJNF-PHXFNYRRSA-N (2s,3s,4s,5r)-2-benzhydryl-3-[(2-methoxy-5-methylsulfinylphenyl)methylamino]-1-azabicyclo[2.2.2]octane-5-carboxylic acid Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(O)=O)([C@@H]1NCC=1C(=CC=C(C=1)S(C)=O)OC)[H])C1=CC=CC=C1 ZBFJTKASKIUJNF-PHXFNYRRSA-N 0.000 claims description 3
- NNQJDQUAJJRYRV-NSIYGSDQSA-N (2s,3s,4s,5r)-2-benzhydryl-3-[(2-methoxy-5-methylsulfonylphenyl)methylamino]-1-azabicyclo[2.2.2]octane-5-carboxylic acid Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(O)=O)([C@@H]1NCC=1C(=CC=C(C=1)S(C)(=O)=O)OC)[H])C1=CC=CC=C1 NNQJDQUAJJRYRV-NSIYGSDQSA-N 0.000 claims description 3
- UGYNIDYASJFWTR-FXZOGHEHSA-N (2s,3s,4s,5r)-2-benzhydryl-3-[(2-methoxy-5-propan-2-ylphenyl)methylamino]-1-azabicyclo[2.2.2]octane-5-carboxylic acid Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(O)=O)([C@@H]1NCC=1C(=CC=C(C=1)C(C)C)OC)[H])C1=CC=CC=C1 UGYNIDYASJFWTR-FXZOGHEHSA-N 0.000 claims description 3
- UCSKUOLGIXJPLU-FXZOGHEHSA-N (2s,3s,4s,5r)-2-benzhydryl-3-[(2-methoxy-5-propylphenyl)methylamino]-1-azabicyclo[2.2.2]octane-5-carboxylic acid Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(O)=O)([C@@H]1NCC=1C(=CC=C(CCC)C=1)OC)[H])C1=CC=CC=C1 UCSKUOLGIXJPLU-FXZOGHEHSA-N 0.000 claims description 3
- HANWCAQDYMDUKN-ATACATFBSA-N (2s,3s,4s,5r)-2-benzhydryl-3-[(5-ethyl-2-methoxyphenyl)methylamino]-1-azabicyclo[2.2.2]octane-5-carboxylic acid Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(O)=O)([C@@H]1NCC=1C(=CC=C(CC)C=1)OC)[H])C1=CC=CC=C1 HANWCAQDYMDUKN-ATACATFBSA-N 0.000 claims description 3
- NOTNLZQKHMFVKX-MTDVLGRSSA-N (2s,3s,4s,5r)-2-benzhydryl-3-[(6-methoxy-6-methylsulfanylcyclohexa-2,4-dien-1-yl)methylamino]-1-azabicyclo[2.2.2]octane-5-carboxylic acid Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(O)=O)([C@@H]1NCC1C(C=CC=C1)(OC)SC)[H])C1=CC=CC=C1 NOTNLZQKHMFVKX-MTDVLGRSSA-N 0.000 claims description 3
- LBYSHULELVFOGE-ATACATFBSA-N (2s,3s,4s,5r)-2-benzhydryl-3-[[5-(dimethylamino)-2-methoxyphenyl]methylamino]-1-azabicyclo[2.2.2]octane-5-carboxylic acid Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(O)=O)([C@@H]1NCC=1C(=CC=C(C=1)N(C)C)OC)[H])C1=CC=CC=C1 LBYSHULELVFOGE-ATACATFBSA-N 0.000 claims description 3
- BNUOLJBGGUPSKO-YVYLOCOQSA-N (2s,3s,4s,5r)-2-benzhydryl-n,n-diethyl-3-[(2-methoxy-5-propan-2-ylphenyl)methylamino]-1-azabicyclo[2.2.2]octane-5-carboxamide Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(=O)N(CC)CC)([C@@H]1NCC=1C(=CC=C(C=1)C(C)C)OC)[H])C1=CC=CC=C1 BNUOLJBGGUPSKO-YVYLOCOQSA-N 0.000 claims description 3
- PQKIWYJYAKTGNP-QGWOSTIUSA-N 1-(4-fluorophenyl)-4-[(2s,3s)-3-[(2-methoxyphenyl)methylamino]-2-phenylpiperidin-1-yl]butan-1-ol Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)N(CCCC(O)C=2C=CC(F)=CC=2)CCC1 PQKIWYJYAKTGNP-QGWOSTIUSA-N 0.000 claims description 3
- NPKIOBYABGRQLF-YTMVLYRLSA-N 2,4-dimethyl-n-(2-methylpropyl)-n-[3-[[[(2s,3s)-2-phenylpiperidin-3-yl]amino]methyl]-4-propan-2-yloxyphenyl]-1,3-thiazole-5-sulfonamide Chemical compound C1([C@@H]2NCCC[C@@H]2NCC=2C(OC(C)C)=CC=C(C=2)N(CC(C)C)S(=O)(=O)C2=C(N=C(C)S2)C)=CC=CC=C1 NPKIOBYABGRQLF-YTMVLYRLSA-N 0.000 claims description 3
- DKWJWICVVLNEFV-UHFFFAOYSA-N 2-benzhydryl-n-[2-methoxy-5-(trifluoromethoxy)phenyl]-2-methyl-1-azabicyclo[2.2.2]octan-3-amine Chemical compound COC1=CC=C(OC(F)(F)F)C=C1NC1C(C(C=2C=CC=CC=2)C=2C=CC=CC=2)(C)N2CCC1CC2 DKWJWICVVLNEFV-UHFFFAOYSA-N 0.000 claims description 3
- XQDSIGDVDWFZPP-UHFFFAOYSA-N 2-phenylpiperidin-1-amine Chemical compound NN1CCCCC1C1=CC=CC=C1 XQDSIGDVDWFZPP-UHFFFAOYSA-N 0.000 claims description 3
- 125000006499 2-trifluoromethoxy benzyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 claims description 3
- HQZONHWUUKPDRH-QGWOSTIUSA-N 4-[(2s,3s)-3-[(2-methoxyphenyl)methylamino]-2-phenylpiperidin-1-yl]-1-phenylbutan-1-ol Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)N(CCCC(O)C=2C=CC=CC=2)CCC1 HQZONHWUUKPDRH-QGWOSTIUSA-N 0.000 claims description 3
- LAOMAAZAXGILTO-WNJJXGMVSA-N 4-[(2s,3s)-3-[(2-methoxyphenyl)methylamino]-2-phenylpiperidin-1-yl]-1-phenylbutan-1-one Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)N(CCCC(=O)C=2C=CC=CC=2)CCC1 LAOMAAZAXGILTO-WNJJXGMVSA-N 0.000 claims description 3
- MBEKBYMBAOKXLY-UPVQGACJSA-N 5-[(2s,3s)-3-[(2-methoxyphenyl)methylamino]-2-phenylpiperidin-1-yl]pentanenitrile Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)N(CCCCC#N)CCC1 MBEKBYMBAOKXLY-UPVQGACJSA-N 0.000 claims description 3
- HIORMPAWFMQDOW-ZCYQVOJMSA-N 6-[(2s,3s)-3-[(2-methoxyphenyl)methylamino]-2-phenylpiperidin-1-yl]hexan-1-ol Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)N(CCCCCCO)CCC1 HIORMPAWFMQDOW-ZCYQVOJMSA-N 0.000 claims description 3
- WUSKHOUAANEBFY-HPZMQGABSA-N 6-[(2s,3s)-3-[(2-methoxyphenyl)methylamino]-2-phenylpiperidin-1-yl]hexane-1,2-diol Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)N(CCCCC(O)CO)CCC1 WUSKHOUAANEBFY-HPZMQGABSA-N 0.000 claims description 3
- ZPRDFJADOFPMGD-WDZYCZAWSA-N C1([C@H]2NCCC[C@H]2C(N)C2=CC(=CC=C2OC(C)C)N(C(C)C)S(=O)(=O)C2=C(N=C(C)S2)C)=CC=CC=C1 Chemical compound C1([C@H]2NCCC[C@H]2C(N)C2=CC(=CC=C2OC(C)C)N(C(C)C)S(=O)(=O)C2=C(N=C(C)S2)C)=CC=CC=C1 ZPRDFJADOFPMGD-WDZYCZAWSA-N 0.000 claims description 3
- JVFPZFUQFWJRAI-OTHQKOMUSA-N N-[3-[amino-[(2S,3S)-2-phenylpiperidin-3-yl]methyl]-4-methoxyphenyl]-N,2,4-trimethyl-1,3-thiazole-5-sulfonamide Chemical compound C1([C@H]2NCCC[C@H]2C(N)C2=CC(=CC=C2OC)N(C)S(=O)(=O)C2=C(N=C(C)S2)C)=CC=CC=C1 JVFPZFUQFWJRAI-OTHQKOMUSA-N 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- JGCMPBRNZDBPGS-IGKIAQTJSA-N ethyl 6-[(2s,3s)-3-[(2-methoxyphenyl)methylamino]-2-phenylpiperidin-1-yl]hexanoate Chemical compound N([C@H]1CCCN([C@H]1C=1C=CC=CC=1)CCCCCC(=O)OCC)CC1=CC=CC=C1OC JGCMPBRNZDBPGS-IGKIAQTJSA-N 0.000 claims description 3
- KXCUGLQCBUEEQE-AHWVRZQESA-N n,2,4-trimethyl-n-[3-[[[(2s,3s)-2-phenylpiperidin-3-yl]amino]methyl]-4-propan-2-yloxyphenyl]-1,3-thiazole-5-sulfonamide Chemical compound C1([C@@H]2NCCC[C@@H]2NCC2=CC(=CC=C2OC(C)C)N(C)S(=O)(=O)C2=C(N=C(C)S2)C)=CC=CC=C1 KXCUGLQCBUEEQE-AHWVRZQESA-N 0.000 claims description 3
- FNYBJRDPAREZDB-GMAHTHKFSA-N n,4,5-trimethyl-n-[3-[[[(2s,3s)-2-phenylpiperidin-3-yl]amino]methyl]-4-(trifluoromethoxy)phenyl]-1,3-thiazole-2-sulfonamide Chemical compound C1([C@@H]2NCCC[C@@H]2NCC=2C(OC(F)(F)F)=CC=C(C=2)N(C)S(=O)(=O)C=2SC(C)=C(C)N=2)=CC=CC=C1 FNYBJRDPAREZDB-GMAHTHKFSA-N 0.000 claims description 3
- XXXAPFHGQOEKLI-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-2,4-diphenylpiperidin-3-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NCCC1C1=CC=CC=C1 XXXAPFHGQOEKLI-UHFFFAOYSA-N 0.000 claims description 3
- SZFRAFLMDAIGLU-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-4-methyl-2-phenylpiperidin-3-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NCCC1C SZFRAFLMDAIGLU-UHFFFAOYSA-N 0.000 claims description 3
- MYORKKSQSYUQSH-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-5-methyl-2-phenylpiperidin-3-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NCC(C)C1 MYORKKSQSYUQSH-UHFFFAOYSA-N 0.000 claims description 3
- DBKJGIXLYZJDMI-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-6-methyl-2-phenylpiperidin-3-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NC(C)CC1 DBKJGIXLYZJDMI-UHFFFAOYSA-N 0.000 claims description 3
- LKNKQNAVJZLIQF-OTHQKOMUSA-N n-[3-[amino-[(2s,3s)-2-phenylpiperidin-3-yl]methyl]-4-methoxyphenyl]-n-(4,5-dimethyl-1,3-thiazol-2-yl)methanesulfonamide Chemical compound C1([C@H]2NCCC[C@H]2C(N)C2=CC(=CC=C2OC)N(C=2SC(C)=C(C)N=2)S(C)(=O)=O)=CC=CC=C1 LKNKQNAVJZLIQF-OTHQKOMUSA-N 0.000 claims description 3
- CPRLSXFVPLMALV-YTMVLYRLSA-N n-[4-[(2s,3s)-3-[(2-methoxyphenyl)methylamino]-2-phenylpiperidin-1-yl]butyl]benzamide Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)N(CCCCNC(=O)C=2C=CC=CC=2)CCC1 CPRLSXFVPLMALV-YTMVLYRLSA-N 0.000 claims description 3
- LHUWCDDBFUABOQ-WEZIJMHWSA-N n-[4-[(2s,3s)-3-[(2-methoxyphenyl)methylamino]-2-phenylpiperidin-1-yl]butyl]naphthalene-2-carboxamide Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)N(CCCCNC(=O)C=2C=C3C=CC=CC3=CC=2)CCC1 LHUWCDDBFUABOQ-WEZIJMHWSA-N 0.000 claims description 3
- HLKDJHNFCHUTOA-BDYUSTAISA-N n-[4-methoxy-3-[[[(2s,3s)-2-phenylpiperidin-3-yl]amino]methyl]phenyl]-2,4-dimethyl-n-(2-methylpropyl)-1,3-thiazole-5-sulfonamide Chemical compound C1([C@@H]2NCCC[C@@H]2NCC2=CC(=CC=C2OC)N(CC(C)C)S(=O)(=O)C2=C(N=C(C)S2)C)=CC=CC=C1 HLKDJHNFCHUTOA-BDYUSTAISA-N 0.000 claims description 3
- VWNODFQKKKCTRU-AHWVRZQESA-N n-[4-methoxy-3-[[[(2s,3s)-2-phenylpiperidin-3-yl]amino]methyl]phenyl]-2,4-dimethyl-n-propan-2-yl-1,3-thiazole-5-sulfonamide Chemical compound C1([C@@H]2NCCC[C@@H]2NCC2=CC(=CC=C2OC)N(C(C)C)S(=O)(=O)C2=C(N=C(C)S2)C)=CC=CC=C1 VWNODFQKKKCTRU-AHWVRZQESA-N 0.000 claims description 3
- RLQOSRPUKJCKQO-JDXGNMNLSA-N n-[5-[(2s,3s)-3-[(2-methoxyphenyl)methylamino]-2-phenylpiperidin-1-yl]pentyl]benzamide Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)N(CCCCCNC(=O)C=2C=CC=CC=2)CCC1 RLQOSRPUKJCKQO-JDXGNMNLSA-N 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 2
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 claims 1
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 23
- 230000036506 anxiety Effects 0.000 description 19
- 239000000902 placebo Substances 0.000 description 10
- 229940068196 placebo Drugs 0.000 description 10
- 230000003542 behavioural effect Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102100024304 Protachykinin-1 Human genes 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 206010011469 Crying Diseases 0.000 description 5
- 208000000810 Separation Anxiety Diseases 0.000 description 5
- 102000003141 Tachykinin Human genes 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000009191 jumping Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108060008037 tachykinin Proteins 0.000 description 5
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 4
- 101800003906 Substance P Proteins 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000001055 chewing effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- OMPCVMLFFSQFIX-CONSDPRKSA-N (2s,3s)-2-benzhydryl-n-[(5-tert-butyl-2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine Chemical compound COC1=CC=C(C(C)(C)C)C=C1CN[C@@H]1[C@H](C(C=2C=CC=CC=2)C=2C=CC=CC=2)N2CCC1CC2 OMPCVMLFFSQFIX-CONSDPRKSA-N 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 2
- 206010001488 Aggression Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010013642 Drooling Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 2
- 208000008630 Sialorrhea Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 208000012761 aggressive behavior Diseases 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960004606 clomipramine Drugs 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 125000001151 peptidyl group Chemical group 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940001470 psychoactive drug Drugs 0.000 description 2
- 239000004089 psychotropic agent Substances 0.000 description 2
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical class C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- LVCKDBYHCLGPDR-LSGCGUROSA-N (2s,3s,4s,5r)-2-benzhydryl-3-[[2-methoxy-5-(trifluoromethoxy)phenyl]methylamino]-1-azabicyclo[2.2.2]octane-5-carboxylic acid Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(O)=O)([C@@H]1NCC=1C(=CC=C(OC(F)(F)F)C=1)OC)[H])C1=CC=CC=C1 LVCKDBYHCLGPDR-LSGCGUROSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- GRBSRKIQJCLYFU-WNJJXGMVSA-N 1-(4-fluorophenyl)-4-[(2s,3s)-3-[(2-methoxyphenyl)methylamino]-2-phenylpiperidin-1-yl]butan-1-one Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)N(CCCC(=O)C=2C=CC(F)=CC=2)CCC1 GRBSRKIQJCLYFU-WNJJXGMVSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000824799 Canis lupus dingo Species 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 206010048533 Hypervigilance Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 101800000399 Neurokinin A Proteins 0.000 description 1
- HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 description 1
- 102400000097 Neurokinin A Human genes 0.000 description 1
- 102000046798 Neurokinin B Human genes 0.000 description 1
- NHXYSAFTNPANFK-HDMCBQFHSA-N Neurokinin B Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(O)=O)C1=CC=CC=C1 NHXYSAFTNPANFK-HDMCBQFHSA-N 0.000 description 1
- 101800002813 Neurokinin-B Proteins 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000669 biting effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000013481 data capture Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940035613 prozac Drugs 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960003660 sertraline hydrochloride Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 239000002462 tachykinin receptor antagonist Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940020965 zoloft Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30669201P | 2001-07-20 | 2001-07-20 | |
| US60/306,692 | 2001-07-20 | ||
| PCT/IB2002/002847 WO2003009848A1 (en) | 2001-07-20 | 2002-07-15 | Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20040029375A true KR20040029375A (ko) | 2004-04-06 |
Family
ID=23186426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2004-7000901A Ceased KR20040029375A (ko) | 2001-07-20 | 2002-07-15 | 개, 고양이 및 말에서 결함있는 행태를 변화시키기 위한ｎｋ-1 수용체 길항제의 용도 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20030139443A1 (https=) |
| EP (1) | EP1411946A1 (https=) |
| JP (1) | JP2005504029A (https=) |
| KR (1) | KR20040029375A (https=) |
| CN (1) | CN1529600A (https=) |
| CA (1) | CA2448722A1 (https=) |
| CZ (1) | CZ200434A3 (https=) |
| HU (1) | HUP0401154A2 (https=) |
| IL (1) | IL158990A0 (https=) |
| PL (1) | PL367944A1 (https=) |
| SK (1) | SK252004A3 (https=) |
| WO (1) | WO2003009848A1 (https=) |
| ZA (1) | ZA200308991B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2554823A1 (en) | 2004-01-30 | 2005-09-09 | Pfizer Products Inc. | Nk-1 receptor antagonists to improve anesthesia recovery |
| LT1713504T (lt) | 2004-01-30 | 2017-09-11 | Zoetis Services Llc | Antimikrobinis konservantas, skirtas multi-dozinėms kompozicijoms, panaudojant beta-ciklodekstrinus, skirtas skystoms vaisto formoms |
| CA2564751A1 (en) * | 2004-04-30 | 2005-11-24 | Schering Corporation | Neuropeptide receptor modulators |
| CN114403042A (zh) * | 2021-12-13 | 2022-04-29 | 深圳先进技术研究院 | 一种大动物焦虑症动物模型 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX18467A (es) * | 1988-11-23 | 1993-07-01 | Pfizer | Agentes terapeuticos de quinuclidinas |
| US5232929A (en) * | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
| FR2677361A1 (fr) * | 1991-06-04 | 1992-12-11 | Adir | Nouveaux peptides et pseudopeptides, derives de tachykinines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| AU657552B2 (en) * | 1991-05-31 | 1995-03-16 | Pfizer Inc. | Quinuclidine as substance P antagonists |
| DE69213451T2 (de) * | 1991-06-20 | 1997-01-09 | Pfizer Inc., New York | Fluoralkoxybenzylaminoderivate stickstoffhaltiger heterocyclen |
| ATE166650T1 (de) * | 1993-03-04 | 1998-06-15 | Pfizer | Spiroazacyclischderivate als substanz p antagonisten |
| DK0623344T3 (da) * | 1993-05-04 | 2000-12-18 | Ceva Sante Animale | Anvendelse af selegilin i veterinær medicin |
| IL109646A0 (en) * | 1993-05-19 | 1994-08-26 | Pfizer | Heteroatom substituted alkyl benzylamino-quinuclidines |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| US6083943A (en) * | 1993-09-17 | 2000-07-04 | Pfizer Inc | Substituted azaheterocyclecarboxylic acid |
| EP1209157A1 (en) * | 1993-09-17 | 2002-05-29 | Pfizer Inc. | Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds |
| US5854262A (en) * | 1993-10-07 | 1998-12-29 | Pfizer Inc. | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists |
| PE45195A1 (es) * | 1994-03-03 | 1996-01-17 | Boehringer Ingelheim Kg | Derivado de aminoacido, procedimiento para su preparacion y composicion farmaceutica que lo contiene |
| US5607936A (en) * | 1994-09-30 | 1997-03-04 | Merck & Co., Inc. | Substituted aryl piperazines as neurokinin antagonists |
| ES2229259T3 (es) * | 1995-01-12 | 2005-04-16 | Glaxo Group Limited | Derivados de piperidina con actividad antagonista de taquiquinina. |
| US5990125A (en) * | 1996-01-19 | 1999-11-23 | Pfizer Inc. | NK-1 receptor antagonists for the treatment of cancer |
| US6117855A (en) * | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
| DE69736390T2 (de) * | 1996-10-07 | 2007-07-26 | Merck Sharp & Dohme Ltd., Hoddesdon | Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum |
| IL130223A (en) * | 1996-12-19 | 2005-09-25 | Aventis Pharma Inc | Heterocyclic substituted pyrrolidine amide derivatives, process for their preparation and pharmaceutical compositions containing them |
| US6156749A (en) * | 1997-12-01 | 2000-12-05 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating movement disorders |
| JP4669095B2 (ja) * | 1999-07-19 | 2011-04-13 | 太陽化学株式会社 | ペットの問題行動抑制組成物 |
| CA2280309C (en) * | 1999-08-13 | 2007-05-08 | William Norton Milgram | Use of adrafinil to treat behavioral problems in aged canines |
| CA2324813A1 (en) * | 1999-11-10 | 2001-05-10 | Susan Beth Sobolov-Jaynes | Combination treatment for depression and anxiety |
| US20020049211A1 (en) * | 2000-09-06 | 2002-04-25 | Sobolov-Jaynes Susan Beth | Combination treatment for depression and anxiety |
-
2002
- 2002-07-15 PL PL02367944A patent/PL367944A1/xx not_active Application Discontinuation
- 2002-07-15 WO PCT/IB2002/002847 patent/WO2003009848A1/en not_active Ceased
- 2002-07-15 CN CNA028141873A patent/CN1529600A/zh active Pending
- 2002-07-15 JP JP2003515240A patent/JP2005504029A/ja not_active Withdrawn
- 2002-07-15 IL IL15899002A patent/IL158990A0/xx unknown
- 2002-07-15 KR KR10-2004-7000901A patent/KR20040029375A/ko not_active Ceased
- 2002-07-15 HU HU0401154A patent/HUP0401154A2/hu unknown
- 2002-07-15 SK SK25-2004A patent/SK252004A3/sk not_active Application Discontinuation
- 2002-07-15 CZ CZ200434A patent/CZ200434A3/cs unknown
- 2002-07-15 EP EP02745741A patent/EP1411946A1/en not_active Withdrawn
- 2002-07-15 CA CA002448722A patent/CA2448722A1/en not_active Abandoned
- 2002-07-19 US US10/199,284 patent/US20030139443A1/en not_active Abandoned
-
2003
- 2003-11-19 ZA ZA200308991A patent/ZA200308991B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL367944A1 (en) | 2005-03-07 |
| CN1529600A (zh) | 2004-09-15 |
| IL158990A0 (en) | 2004-05-12 |
| HUP0401154A2 (hu) | 2004-10-28 |
| CA2448722A1 (en) | 2003-02-06 |
| JP2005504029A (ja) | 2005-02-10 |
| EP1411946A1 (en) | 2004-04-28 |
| CZ200434A3 (cs) | 2005-02-16 |
| US20030139443A1 (en) | 2003-07-24 |
| ZA200308991B (en) | 2004-11-19 |
| SK252004A3 (sk) | 2005-03-04 |
| WO2003009848A1 (en) | 2003-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gatley et al. | Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans | |
| US10632116B2 (en) | Combinations of serotonin receptor agonists for treatment of movement disorders | |
| Ogata¹ et al. | Selective serotonin reuptake inhibitors | |
| JPH08225464A (ja) | 嘔吐治療用ｎｋ−１受容体アンタゴニスト及び５ｈｔ３受容体アンタゴニスト | |
| JP2001523245A (ja) | 肥満を治療するためのｎｋ−１受容体拮抗薬およびｓｓｒｉの使用 | |
| NZ238277A (en) | Veterinary agent for retarding age-dependent deterioration comprising 1-deprenyl | |
| US20220096449A1 (en) | Method of treatment with tradipitant | |
| KR20210107729A (ko) | 운동 장애의 치료 | |
| JP2009518423A (ja) | 統合失調症の副作用および陰性症状を治療するためのｃｂ１アンタゴニストの使用 | |
| US20140221385A1 (en) | Combinations of serotonin receptor agonists for treatment of movement disorders | |
| US20080194631A1 (en) | Medicament For the Treatment of Central Nervous System Disorders | |
| Nicolodi et al. | Central cholinergic challenging of migraine by testing second‐generation anticholinesterase drugs | |
| KR20040029375A (ko) | 개, 고양이 및 말에서 결함있는 행태를 변화시키기 위한ｎｋ-1 수용체 길항제의 용도 | |
| JP7588773B2 (ja) | グルタミン酸２ｂ受容体拮抗薬及びシグマ受容体作動薬の鎮咳薬としての使用 | |
| Hatcher et al. | Sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, reverses delay-induced deficits in the T-maze | |
| US6511982B2 (en) | Treatment of pain | |
| AU2002317436A1 (en) | Use of NK-1 receptor antagonists to modify unwanted behaviour in dogs, cats and horses | |
| JP2005504029A5 (https=) | ||
| Wooters et al. | Nicotinic receptors differentially modulate the induction and expression of behavioral sensitization to methylphenidate in rats | |
| US20060173071A1 (en) | Mast cell stabilizers used to inhibit laminitis | |
| HK1065256A (en) | Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses | |
| Maan | Comparison of Methamphetamine and MDMA Extended Access Self-administration: Acquisition, Maintenance, and Response patterns | |
| MXPA98001905A (en) | The use of an antagonist of the nk-1 receptor in the preparation of a composition for gene therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| AMND | Amendment | ||
| PA0105 | International application |
Patent event date: 20040119 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20040119 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20050912 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20060103 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20050912 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| AMND | Amendment | ||
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20060202 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20060103 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20061128 Appeal identifier: 2006101000926 Request date: 20060202 |
|
| PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20060202 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20060202 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20051111 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 20040119 Patent event code: PB09011R02I |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20060308 Patent event code: PE09021S01D |
|
| B601 | Maintenance of original decision after re-examination before a trial | ||
| PB0601 | Maintenance of original decision after re-examination before a trial | ||
| J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20060202 Effective date: 20061128 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S01D Patent event date: 20061130 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20060202 Decision date: 20061128 Appeal identifier: 2006101000926 |